Search Results
Oct 22, 2025, 10:11 ET Jordan S. Orange, MD, PhD Rejoins Children's Hospital of Philadelphia in a New Role as Pediatrician-in-Chief and Chair of the Department of Pediatrics
Joseph W. St. Geme III, MD, Physician-in-Chief at CHOP. "Dr. Orange possesses unparalleled expertise as both a clinician and a researcher. I am confident that his unwavering
More news about: Children's Hospital of Philadelphia
Oct 22, 2025, 09:00 ET FOUNDATION SOURCE EXPANDS ITS TECH-ENABLED PHILANTHROPIC SERVICES WITH LAUNCH OF NEW 501(C)(3) FISCAL SPONSOR
Joseph Mrak III, CEO of Foundation Source. "This new offering from FSCF enables changemakers to focus on their mission while giving donors more opportunities to support
More news about: Foundation Source
Oct 22, 2025, 08:14 ET REPUBLIC OF URUGUAY - ANNOUNCEMENT OF TENDER OFFERS
cancellation of your tender and in your remaining obligation to purchase your allocation of New Bonds in respect of your related Indication of Interest and/or (iii) in the delivery of a buy-in notice for the purchase of such Old Global Bonds, executed in accordance with customary brokerage practices for corporate
More news about: Republic of Uruguay
Oct 22, 2025, 08:00 ET Burford Capital YPF Matter Update
Circuit decision affirms the District Court and is released six months after oral argument; (ii) that rehearing is sought and denied 45 days thereafter; (iii) that the Supreme Court's review is sought; and (iv) that there is no CVSG. Based on those assumptions, the timing would unfold
More news about: Burford Capital Limited
Oct 22, 2025, 08:00 ET Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin Accepted for Late-Breaking Oral Abstract Presentation at ACAAI 2025 Annual Scientific Meeting
including negative safety and efficacy findings in future clinical studies (notwithstanding positive findings in earlier preclinical and clinical studies); (iii) rezpegaldesleukin, NKTR-0165, NKTR-0166, NKTR-422 and NKTR-255 are in clinical development and the risk of failure is high and can unexpectedly occur
More news about: Nektar Therapeutics
Oct 22, 2025, 08:00 ET Astellas Presents Preliminary Real-World VEOZAH™ (fezolinetant) Data From OPTION-VMS Phase IV Observational Study
(i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue
More news about: Astellas Pharma Inc.
Oct 22, 2025, 07:00 ET Martin L. Kaiser III's 'Help Yourself! ... a Story of FBI Corruption' set to appear at the 2025 Frankfurt International Book Fair
COCKEYSVILLE, Md., Oct. 22, 2025 /PRNewswire/ -- Martin L. Kaiser III, the author of "Odyssey of an Eavesdropper," returns to the publishing scene with "
More news about: Trafford Publishing
Oct 22, 2025, 07:00 ET Alkermes plc Announces Agreement to Acquire Avadel Pharmaceuticals plc
the boards of directors of both Alkermes and Avadel, is expected to close in the first quarter of 2026, subject to the Conditions set out in Appendix III of this Announcement, including certain regulatory approvals and approvals by Avadel's shareholders. J.P. Morgan is acting as
More news about: Alkermes plc; Avadel Pharmaceuticals plc
Oct 22, 2025, 06:30 ET Hyperscale Data Regains Compliance with NYSE American Continued Listing Standards
American. We have and will continue to work on driving stockholder value and right sizing the Company's long-term public valuation," said Milton "Todd" Ault III, Founder and Executive Chairman of the Company. For more information on Hyperscale Data and its subsidiaries, Hyperscale Data
More news about: Hyperscale Data Inc.
Oct 22, 2025, 06:15 ET Taylor Morrison Reports Third Quarter 2025 Results
information relating to: (i) adjusted net income and adjusted earnings per common share, (ii) adjusted income before income taxes and related margin, (iii) adjusted home closings gross margin, (iv) EBITDA and Adjusted EBITDA and (v) net homebuilding debt to capitalization ratio. Adjusted
More news about: Taylor Morrison Home Corp.
Oct 22, 2025, 04:10 ET Boliden resolves to repurchase its shares
on one or several occasions and shall commence no earlier than 22 October 2025 and shall end no later than 24 October 2025. iii. A maximum of 130,000 shares in the Company may be repurchased for a total amount of up to SEK 60 million in order to ensure delivery of shares
More news about: Boliden
Oct 21, 2025, 19:30 ET PADCEV™ (enfortumab vedotin-ejfv) Plus KEYTRUDA® (pembrolizumab) sBLA Granted FDA Priority Review for Treatment of Certain Patients with Muscle-Invasive Bladder Cancer
(i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, (ii) currency exchange rate fluctuations, (iii) delays in new product launches, (iv) the inability of Astellas to market existing and new products effectively, (v) the inability of Astellas to continue
More news about: Astellas Pharma Inc.
Oct 21, 2025, 17:58 ET CEA Industries ($BNC) Crosses Half-Million BNB Milestone
(i) the longevity of the Company's position as the largest BNB treasury in the world; (ii) the long-term growth and adoption of the BNB ecosystem; (iii) BNC's role in advancing BNB's global adoption; (iv) the growth of interest from institutional partners and investors worldwide; (v) BNC being the most
More news about: CEA Industries Inc.
Oct 21, 2025, 17:31 ET Emphysema Market Analysis Reveals Promising Growth Opportunities and Trends During the Forecast Period (2025-2034) | DelveInsight
Itepekimab through a global partnership. GSK's Depemokimab is the first ultra-long-acting biologic in Phase III trials, exhibiting strong binding affinity and potency against interleukin-5 (IL-5), which enables dosing intervals of up to six months. IL-5 is a central
More news about: DelveInsight Business Research, LLP
Oct 21, 2025, 16:30 ET EQT Reports Third Quarter 2025 Results
Condensed Consolidated Cash Flows included in EQT Corporation's Quarterly Reports on Form 10-Q for the quarters ended June 30, 2025 and March 31, 2025 and (iii) the Statements of Consolidated Cash Flows included in EQT Corporation's Annual Report on Form 10-K for the year ended December 31, 2024.
More news about: EQT Corporation (EQT-IR)
Oct 21, 2025, 16:15 ET Construction Partners, Inc. Announces Preliminary Fiscal 2025 Financial Results and Introduces Fiscal 2026 Outlook
outlook ranges that will be discussed during tomorrow's Analyst Day event in Raleigh, North Carolina. Fred J. (Jule) Smith, III, the Company's President and Chief Executive Officer, said, "Today we are announcing our preliminary fiscal 2025 financial results, reflecting strong
More news about: Construction Partners, Inc.
Oct 21, 2025, 16:15 ET Perimeter Medical Imaging AI Joins American Society of Breast Surgeons' Annual Strategic Futures Forum
material assumptions, including but not limited to (i) the accuracy of Perimeter's financial projections; (ii) obtaining positive results from trials; (iii) obtaining necessary regulatory approvals; and (iv) general business, market, and economic conditions. Further risks, uncertainties and assumptions include,
More news about: Perimeter Medical Imaging AI Inc.
Oct 21, 2025, 16:00 ET American Safety Institute Acquires Coaching Systems, Creating a Platform for Transportation Training & Compliance
respect for the Coaching Systems team and training content, and we are excited for the impact we can make together." Grey Jones III, President of Coaching Systems, added: "Joining with ASI allows us to scale our impact while staying true to our values of customer service and quality
More news about: American Safety Institute
Oct 21, 2025, 15:50 ET The College of Saint Benedict to add flag football this spring
Of course, interest in football at CSB and SJU is already high. The Saint John's football team is a perennial national power in NCAA Division III and the Johnnies are routinely among the nation's leaders in attendance at that level. "We're committed to continuing to grow
More news about: College of Saint Benedict and Saint John’s University
Oct 21, 2025, 13:18 ET Norris McLaughlin, P.A. Allentown Office Grows, Adding Associates Peter G. Manakos and Vivian S. Hadian
Theodore J. Zeller III, Esq., Chair of the Liquor Law Practice Group. "He understands the stakes for our clients and brings a level of empathy and insight that's hard to
More news about: Norris McLaughlin, P.A
Oct 21, 2025, 10:54 ET Caterpillar Invests in U.S. Manufacturing and Future Workforce Skills Training
industries we serve; (ii) commodity price changes, material price increases, fluctuations in demand for our products or significant shortages of material; (iii) government monetary or fiscal policies; (iv) political and economic risks, commercial instability and events beyond our control in the countries in
More news about: Caterpillar Inc.
Oct 21, 2025, 09:00 ET Contact Levi & Korsinsky by October 28, 2025 Deadline to Join Class Action Against Dow Inc.(DOW)
pricing pressures, softening global sales and demand for the Company's products, and an oversupply of products in the Company's global markets; and (iii) as a result, defendants' public statements were materially false and misleading at all relevant times. WHAT'S
More news about: Levi & Korsinsky, LLP
Oct 21, 2025, 09:00 ET Shareholders that lost money on Savara Inc. (SVRA) should contact Levi & Korsinsky about pending Class Action - SVRA
regarding MOLBREEVI's chemistry, manufacturing, and/or controls; (ii) accordingly, FDA was unlikely to approve the MOLBREEVI BLA in its current form; (iii) foregoing made it unlikely that Savara would complete its submission of the MOLBREEVI BLA within the timeframe it had represented to investors; (iv)
More news about: Levi & Korsinsky, LLP
Oct 21, 2025, 09:00 ET Fluor Corporation Class Action: Levi & Korsinsky Reminds Fluor Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of November 14, 2025 - FLR
hesitation around economic uncertainty, was having, or was likely to have, a significant negative impact on the Company's business and financial results; (iii) accordingly, Fluor's financial guidance for FY 2025 was unreliable and/or unrealistic, the effectiveness of the Company's risk mitigation strategy was
More news about: Levi & Korsinsky, LLP
Oct 21, 2025, 09:00 ET Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of October 21, 2025 in Nutex Health Inc. Lawsuit - NUTX
that they were the product of fraudulent conduct, revenues attributable to the Company's engagement with HaloMD in the IDR process were unsustainable; (iii) in addition, the Company overstated the extent to which it had remediated, and/or its ability to remediate, the material weaknesses in its internal
More news about: Levi & Korsinsky, LLP